Clinical Trial Search

Primary: Feasibility of Acquiring In-vivo High-Resolution Microendoscopy (HRME) Images of Cervix Prior to Conization

Primary: Number of Participants With Dose Limiting Toxicities (DLTs) — 0; 1; 0 Participants

Primary: Incidence of Objective Response — 32; 36; 30; 0 Participants — p=0.043

Primary: Feasibility of Intravaginal Use 5-FU and Imiquimod on Alternating Weeks in Women With Biopsy Confirmed High Grade Cervical Squamous Intraepithelial Lesions. — 4; 1…

Primary: Cumulative Number of Participants Diagnosed by the Community Pathologist With Cervical Intraepithelial Neoplasia Grade 2 or Higher (CIN2+): "Community-based CIN2+"…

Primary: Incidence of HPV 6/11/16/18-related Cervical Intraepithelial Neoplasia (CIN)(Any Grade), Adenocarcinoma In Situ (AIS) or Cervical Cancer — 0; 1.2 incidence rate per 100…

Primary: Overall Survival at 2 Years and 5 Years — 93; 85 percentage of participants

Primary: Percentage of Participants With Confirmed Objective Response (OR) as Assessed by the Independent Review Committee (IRC) — 23.8 Percentage of Participants — p=0.0002

Primary: Number of Patients With Progression-free Survival at 2 Years — 19 Participants

Primary: Incidence of the Composite Endpoint of Human Papillomavirus (HPV) 16/18-related Cervical Intraepithelial Neoplasia (CIN) 2 or Worse in the Base Study — 0.0; 0.4…

Primary: Tumor Response — 1; 7; 17; 34 participants

Primary: Histologic Regression — 40; 34.1 percentage of participants

Primary: HPV-Specific T Cell Response Rate — 0.333 proportion of participants

Primary: Number of Participants With Serious Adverse Events — 0; 0; 0; 0 Participants

Primary: Tumor Response — 0; 4; 16; 7 participants

Primary: Proportion of Patients With Objective Tumor Response Rate (Complete Response [CR] or Partial Response [PR]) Using RECIST Version 1.0 — 10; 0 participants

Primary: Percentage of Participants With Best Overall Response According to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 — 2.8 percentage of participants

Primary: Phase 1: Number of Participants Experiencing Dose-limiting Toxicities (DLTs) for Balstilimab — 0; 0; 0; 0 Participants

Primary: Number of Patients With Measurable Concentration of Gemcitabine in Uterine Vein (dFdC) — 5 Participants

Primary: Overall Survival (OS) — 11.7; 8.5 Months — p=<0.00001

Primary: Toxicity (Number of Participants With Serious Adverse Events) — 10 Participants

Primary: Histologic Response in Endometrial Adenocarcinomas of the Uterine Corpus That Are Progesterone Receptor Positive Compared With Those That Are Progesterone Receptor…

Primary: Sensitivity of Scanning a/LCI Probe to Detect Cervical Dysplasia as Measured by Percentage of Correctly Identified Positive Biopsies — 90.3; 100.0 percentage of correct…

Primary: Number of Patients With Interferometric Data Acquired From Cervical Epithelium — 3; 41 patients

Primary: Acceptability of Self-Collection Paired With Mobile Mammography — 33 Participants

Primary: Progression-free Survival Greater Than 6 Months — 30; 5 participants

Primary: Patients With Objective Tumor Response Rate (Complete Response [CR] or Partial Response [PR]) Using RECIST Version 1.0 — 1; 16 participants

Primary: Number of Adverse Events, Graded According to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.0 — 56 Adverse Events

Primary: HPV Identification — 95; 142; 78 biopsies

Primary: Confirmed Response Rate (Complete Response + Partial Response) According to RECIST Version 1.1 — 0 percentage of patients